Dogwood Therapeutics, Inc.
DWTX
$5.37
$1.1025.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 195.93% | 140.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 227.75% | 115.11% | |||
| Operating Income | -227.75% | -115.11% | |||
| Income Before Tax | -238.86% | -117.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -238.84% | -117.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -238.84% | -117.25% | |||
| EBIT | -227.75% | -115.11% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -206.18% | -79.23% | |||
| Normalized Basic EPS | -187.11% | -79.23% | |||
| EPS Diluted | -206.18% | -79.23% | |||
| Normalized Diluted EPS | -187.11% | -79.23% | |||
| Average Basic Shares Outstanding | 18.03% | 21.21% | |||
| Average Diluted Shares Outstanding | 18.03% | 21.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||